Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 184

The DOI matches its Crossref record.

Phenotypic and Functional Analysis of Dendritic Cells and Clinical Outcome in Patients With High-Risk Melanoma Treated With Adjuvant Granulocyte Macrophage Colony-Stimulating Factor

Daud, Adil I., Mirza, Noweeda, Lenox, Brianna, Andrews, Stephanie, Urbas, Patricia, Gao, Gui X., Lee, Ji-Hyun, Sondak, Vernon K., Riker, Adam I., DeConti, Ronald C., Gabrilovich, Dmitry · 2008 · Journal of Clinical Oncology

Abstract

Purpose: Granulocyte macrophage colony-stimulating factor (GM-CSF) can induce differentiation of dendritic cells (DCs) in preclinical models. We hypothesized that GM-CSF–stimulated DC differentiation may result in clinical benefit in patients with high-risk melanoma. Patients and Methods: We conducted a prospective trial in patients with high-risk (stage III B/C, IV), resected melanoma, with GM-CSF 125 μg/m 2/d administered for 14 days every 28 days. Patients underwent clinical restaging every four cycles, with DC analysis performed at baseline and at 2, 4, 8, and 12 weeks. Results: Of 42 patients enrolled, 39 were assessable for clinical outcome and DC analysis. Median overall survival was 65 months (95% CI, 43 to 67 months) and recurrence-free survival was 5.6 months (95% CI, 3 to 11 months). GM-CSF treatment caused an increase in mature DCs, first identified after 2 weeks of treatment, normalizing by 4 weeks. Patients with decreased DCs at baseline had significant increases in DC number and function compared with those with “normal” parameters at baseline. No change was observed in the number of myeloid-derived suppressor cells (MDSCs). Early recurrence (< 90 days) correlated with a decreased effect of GM-CSF on host DCs, compared with late or no (evidence of) recurrence. Conclusion: GM-CSF treatment was associated with a transient increase in mature DCs, but not MDSCs. Greater increase of DCs was associated with remission or delayed recurrence. The prolonged overall survival observed warrants further exploration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2007.13.9048

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 26

  1. Cairo MS: Review of G-CSF and GM-CSF: Effects on neonatal neutrophil kinetics. Am J Pediatr Hematol Oncol 11:238,1989-244,
  2. 10.1200/JCO.2000.18.8.1614 · doi:10.1200/jco.2000.18.8.1614
  3. 10.1517/14712598.5.3.293 · DOI
  4. 10.1038/sj.cr.7310017 · DOI · Paper page
  5. 10.1038/nri1498 · DOI · Paper page
  6. 10.1158/0008-5472.CAN-06-1690 · DOI · Paper page
  7. 10.1038/sj.onc.1206459 · DOI · Paper page
  8. 10.1097/00002371-199903000-00008 · doi:10.1097/00002371-199903000-00008
  9. 10.1007/s10875-006-9033-3 · doi:10.1007/s10875-006-9033-3
  10. 10.1093/annonc/mdl158 · DOI · Paper page
  11. Morton D: Results of multicenter randomized phase III trial of Canvaxin versus BCG in patients with resected stage III or stage IV melanoma. Presented at the 59th Annual Cancer Symposium of the Society for Surgical Oncology , San Diego, CA, March 23-26, 2006
  12. 10.1200/JCO.2000.18.8.1603 · doi:10.1200/jco.2000.18.8.1603
  13. 10.1177/107327480501200403 · DOI
  14. 10.1200/JCO.2002.01.151 · doi:10.1200/jco.2002.01.151
  15. 10.1200/JCO.2001.19.16.3635 · DOI · Paper page
  16. 10.1177/107327480601300309 · doi:10.1177/107327480601300309
  17. 10.1002/cncr.21835 · DOI
  18. 10.1200/JCO.1998.16.3.1103 · DOI · Paper page
  19. 10.1177/107327480601300308 · DOI
  20. 10.1080/08820130600803429 · DOI · Paper page
  21. 10.1158/1078-0432.CCR-07-0409 · DOI · Paper page
  22. 10.4049/jimmunol.166.1.678 · DOI · Paper page
  23. 10.1158/0008-5472.CAN-04-0757 · DOI · Paper page
  24. 10.1016/S0959-8049(03)00131-X · doi:10.1016/s0959-8049(03)00131-x
  25. 10.1200/JCO.2006.08.5829 · DOI · Paper page
  26. 10.1016/S0305-7372(03)00074-4 · DOI · Paper page

Cited by

See all 184

Metadata

Authors
Daud, A. I., Mirza, N., Lenox, B., Andrews, S., Urbas, P., Gao, G. X., Lee, J.-H., Sondak, V. K., Riker, A. I., DeConti, R. C., & Gabrilovich, D.
Venue
Journal of Clinical Oncology
Published
2008-07-01
Volume
26
Issue
19
Pages
3235-3241
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2117933504
Cited by
184
References
0
FWCI
7.03
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phenotypic and Functional Analysis of Dendritic Cells and Clinical Outcome in Patients With High-Risk Melanoma Treated With Adjuvant Granulocyte Macrophage Colony-Stimulating Factor. https://app.cochat.ai/papers/10.1200/jco.2007.13.9048
The paper
Daud, A. I., Mirza, N., Lenox, B., Andrews, S., Urbas, P., Gao, G. X., Lee, J.-H., Sondak, V. K., Riker, A. I., DeConti, R. C., & Gabrilovich, D. (2008). Phenotypic and Functional Analysis of Dendritic Cells and Clinical Outcome in Patients With High-Risk Melanoma Treated With Adjuvant Granulocyte Macrophage Colony-Stimulating Factor. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.13.9048

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.